sleep questionnaire or on the derived MOS sleep scales. Significant improvement in the abatacept group compared to control on sleep adequacy, sleep disturbance, somnolence and both sleep problem indices I and II were found. For both studies, sleep quantity was not significantly difference between treatment groups, but optimal sleep significantly improved in the abatacept vs control group: ATTAIN (18% vs -12%, p < 0.0001) and AIM (16% vs 5%, p = 0.0214). CONCLUSION: Treatment with abatacept improves several different aspects of sleep in RA patients. In particular, sleep disturbance and sleep problems given by index II are reduced, and optimal sleep is improved.
PMS38 ESTIMATING WORK PRODUCTIVITY: EFFECTS OF TRAMADOL EXTENDED-RELEASE TREATMENT
We used a Markov model to estimate employable life-years using data from ASPIRE, a randomized clinical trial comparing the efficacy and safety of infliximab + methotrexate (MTX) (IFX group) and placebo + MTX (MTX group) among early RA patients. Employability state was defined as 'unemployable' if patients were unemployed and felt unable to work even if a job was available or 'employable' if patients were employed or felt well enough to work if a job were available. The one-year transition probability of employability was estimated using a logistic regression model, and loss of employable life-years was estimated using a two-state Markov model. RESULTS: For a patient at age 45 years, 31.4 % of female and 29.7% of male were unemployable using the regression model. For patients starting at age 45 and employable, the probability of remaining employable after one-year of treatment was 0.928 in males and 0.905 in females in the IFX group, and 0.899 in males and 0.867 in females in the MTX groups, respectively. For patients unemployable, the probability to be employable after one-year treatment was 0.481 in males and 0.405 in females in the IFX groups, and 0.390 in males and 0.319 in females in the MTX groups, respectively. In the Markov model, after 10 years at age 55, 18.5% of females and 14.1% of males in the IFX groups, and 30.7% of females and 24.2% of males in the MTX groups will be unemployable. On average, 0.99 employable life-years will be saved per patient over 10 years in IFX-treated patients compared to MTX-treated patients. CONCLUSION: This analysis presents a new method to estimate employable life-years using a Markov model, and demonstrated that IFX-treated patients could gain economic benefit by retaining employability over time.
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PMS40 ORAL VS INJECTABLE TREATMENTS: PATIENT PREFERENCE IN BRAZILIAN PATIENTS
Boscatti FHG Produtos Roche Químicos e Farmacêuticos S.A, São Paulo, SP, Brazil OBJECTIVE: To assess the preference of Brazilians for drugs with different dosing and methods of application to treat chronic diseases, such as osteoporosis. The assessed product types were: once-monthly oral, injection once every three months, and once-yearly injection. METHODS: Quantitative study performed through personal and individual interviews. A representative sample of the study population (N = 392 subjects) was used. Subjects over 45 years old were interviewed. A 14-item structured questionnaire was used. A card with the drug characteristics (dosing, cares of administration, side effects and annual treatment cost) was shown to the interviewed subjects. RESULTS: Fourty-four percent of the interviewed subjects were male and 56% were female. Sixty percent of the interviewed subjects were between 45 and 59 years old, and the other 40% were 60 years old or more. Fourteen percent of the interviewed subjects belonged to the Brazilian socioeconomic classification "A", followed by 39% in the classification "B", and 47% in the classification "C". Twenty-eight percent had higher education, followed by 29% with secondary education, and 42% with primary education. Ninety-three percent of the interviewed subjects do not usually take injection drugs. For treatment of chronic diseases, 72% of the patients prefer oral drugs, 16% prefer injection drugs diluted in serum, 9% prefer injection drugs, and 3% did not inform their preference. These percentages remained the same when dosing, side effects and prices were disclosed. 83% of the patients who chose oral drug did it so by convenience of the dosing, 21% of them also think that oral drugs have fewer side effects than injection drugs. Generically comparing (not considering the card with product profiles) oral and injection drugs, 78% of the population prefer oral treatments. CONCLU-SION: If patients are given the chance to choose between oral or injection drugs to treat chronic diseases, 78% prefer oral drugs instead of injection ones.
PMS41 UTILIZATION AND COSTS OF DRUGS AND OFFICE SERVICES AMONG RECIPIENTS OF MEDICAID WITH RHEUMATOID ARTHRITIS WITH VERSUS WITHOUT COMORBID DEPRESSION
Khanna R 1 , Smith MJ 1 , Kamal KM 2 1 West Virginia University, Morgantown, WV, USA, 2 Duquesne University, Pittsburgh, PA, USA OBJECTIVE: To determine the differences in the patterns and costs of health care utilization between recipients with Rheumatoid Arthritis (RA) with versus without comorbid depression enrolled in a state Medicaid program. METHODS: A retrospective cross-sectional analysis of a de-identified state Medicaid fee-for-service administrative claims dataset was conducted. The target population included recipients between 15-64 years old who were continuously eligible for benefits between January 1, 2002 and December 31, 2003 . Recipients with at least one medical services claim with a primary diagnosis of RA in 2002 were selected. The sample was then dichotomized between those with versus without a medical claim with a primary diagnosis of depression during 2002. Data from calendar year 2003 was used to compare the patterns of RA-related office services and prescription medication utilization and related costs between the two groups. RESULTS: There were 763 recipients identified with RA, of whom 244 (31.9%) had comorbid depression. A significantly (p < 0.05) higher proportion of recipients 21-44 years of age (41.9%), females (34.4%), and whites (32.0%) with RA had comorbid depression. Negative binomial regression controlling for demographic variables and comorbidities showed the frequency of office visit utilization was significantly (p < 0.05) lower for recipients with comorbid depression than those without depression. A significantly (p < 0.05) higher proportion of recipients without depression than with depression had a claim for a DMARD (49.4% versus 31.9%) and a biologic agent (17.0% versus 10.0%). The average annual amount paid by Medicaid per recipient for the use of office services and prescription medications was significantly (p < 0.05) higher for recipients without depression ($2914) than with depression ($2049). CONCLU-SION: Roughly one-third of the recipients with RA had comorbid depression. The use of primary care office services and prescription medications that can slow the progression of RA was lower among recipients with depression than without depression.
